JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Contribution of Immunoscore to Survival Prediction in Pancreatic Ductal Adenocarcinoma

  • 0Department of Surgery, Shiga University of Medical Science, Shiga, Japan.
Anticancer Research +

|

September 30, 2024

|

September 30, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

A high Immunoscore (IS) in pancreatic ductal adenocarcinoma (PDAC) indicates more tumor-infiltrating lymphocytes (TILs) and predicts better survival and recurrence outcomes. This immune marker is valuable for patients undergoing primary tumor resection.

Area Of Science

  • Oncology
  • Immunology
  • Cancer Research

Background

  • Tumor-infiltrating lymphocytes (TILs) are prognostic in colorectal cancer but their role in pancreatic cancer is unclear.
  • The Immunoscore (IS) quantifies TILs at the tumor core (CT) and invasive margin (IM).
  • Assessing IS in pancreatic ductal adenocarcinoma (PDAC) can offer new insights into tumor immunity.

Purpose Of The Study

  • To evaluate the relationship between Immunoscore (IS) and prognosis in pancreatic ductal adenocarcinoma (PDAC).
  • To determine if IS can predict survival and recurrence in PDAC patients.
  • To investigate the prognostic value of IS in patients receiving preoperative chemotherapy.

Main Methods

  • Immunohistochemistry was used to analyze IS in surgical tissue blocks from 131 PDAC patients.
  • The study correlated IS levels with overall survival (OS) and relapse-free survival (RFS).
  • Multivariate logistic regression models adjusted for clinical pathology data were employed.

Main Results

  • High IS in both CT and IM was significantly associated with prolonged OS and RFS (p<0.01).
  • IS independently predicted survival and recurrence in PDAC patients (p<0.01).
  • In patients receiving preoperative chemotherapy, high IS correlated with significantly longer OS and RFS (p<0.01).

Conclusions

  • Immunoscore (IS) assessed by immunohistochemistry may serve as a valuable prognostic marker for PDAC.
  • IS can help predict outcomes for patients with PDAC undergoing primary tumor resection.
  • Quantifying TILs via IS offers potential for improved patient management in PDAC.

Keywords: